MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
747.52%
Quick Ratio
747.52%
Cash Ratio
718.28%
Debt to Asset Ratio
139.30%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • In-process research and developm...
    • Goodwill
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Contingent value rights liabilit...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
147,606
118,641
125,139
143,384
Accounts receivable
196
261
1,115
722
Prepaid expenses and other current assets
5,813
3,137
3,022
3,154
Total current assets
153,615
122,039
129,276
147,260
Property and equipment, net
11,311
11,637
12,185
12,394
Right-of-use assets, net
5,124
5,366
5,601
4,972
In-process research and development asset
93,900
93,900
93,900
150,600
Goodwill
48,163
48,163
48,163
48,163
Long-term restricted cash
1,735
1,735
1,735
1,735
Investment
-
-
0
2,000
Long-term prepaid expenses and other assets
4,780
5,551
5,551
5,551
Total assets
318,628
288,391
296,411
372,675
Accounts payable
1,046
1,598
1,288
2,225
Accrued expenses and other current liabilities
15,142
10,161
9,498
7,702
Lease liabilities
4,197
4,186
4,151
3,876
Contingent value right liability
-
-
0
0
Warrant liability
165
-
-
-
Total current liabilities
20,550
15,945
14,937
13,803
Lease liabilities, net of current portion
6,805
7,669
8,525
8,727
Warrant liability, net of current portion
0
47
141
-
Warrant liability
-
-
-
848
Long-term debt, net
52,851
-
-
-
Contingent value rights liability
356,700
405,900
392,100
369,000
Deferred tax liabilities, net
6,948
6,948
6,948
16,141
Total liabilities
443,854
436,509
422,651
408,519
Preferred stock, value, issued-Series APreferred Stock
0
0
0
0
Preferred stock, value, issued-Series BPreferred Stock
0
0
0
0
Preferred stock, value, issued
0
0
0
0
Common stock, 0.0001 par value 350,000,000 shares authorized as of june 30, 2026 and december 31, 2025 30,037,962 and 26,011,106 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
3
3
3
3
Additional paid-in capital
725,165
718,017
700,706
698,537
Accumulated deficit
-845,786
-861,555
-822,373
-729,797
Accumulated other comprehensive loss
-4,608
-4,583
-4,576
-4,587
Total stockholders deficit
-125,226
-148,118
-126,240
-35,844
Total liabilities and stockholders deficit
318,628
288,391
296,411
372,675
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$147,606K (-7.93%↓ Y/Y)Prepaid expenses andother current assets$5,813K (113.95%↑ Y/Y)Accounts receivable$196K (-44.63%↓ Y/Y)Total current assets$153,615K (-5.99%↓ Y/Y)In-process research anddevelopment asset$93,900K (-37.65%↓ Y/Y)Goodwill$48,163K (0.00%↑ Y/Y)Property and equipment,net$11,311K (-7.93%↓ Y/Y)Right-of-use assets, net$5,124K (-0.77%↓ Y/Y)Long-term prepaidexpenses and other assets$4,780K Long-term restricted cash$1,735K (0.00%↑ Y/Y)Total assets$318,628K (-18.07%↓ Y/Y)Accumulated deficit-$845,786K (-21.89%↓ Y/Y)Accumulated othercomprehensive loss-$4,608K (-0.68%↓ Y/Y)Total liabilities andstockholders deficit$318,628K (-18.07%↓ Y/Y)Total stockholdersdeficit-$125,226K (-4855.52%↓ Y/Y)Additional paid-in capital$725,165K (4.20%↑ Y/Y)Common stock, 0.0001par value...$3K (0.00%↑ Y/Y)Total liabilities$443,854K (13.40%↑ Y/Y)Contingent value rightsliability$356,700K (1.31%↑ Y/Y)Long-term debt, net$52,851K Total currentliabilities$20,550K (67.67%↑ Y/Y)Deferred taxliabilities, net$6,948K (-56.95%↓ Y/Y)Lease liabilities,net of current...$6,805K (-28.81%↓ Y/Y)Accrued expenses andother current...$15,142K (88.99%↑ Y/Y)Lease liabilities$4,197K (10.74%↑ Y/Y)Accounts payable$1,046K (130.40%↑ Y/Y)Warrant liability$165K

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics, Inc. (RNAC)